newsfilter
← Latest News
GlobeNewswire·

Avicanna Reports Q2 2024

Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc.